ALNY at a glance
Alnylam Pharmaceuticals (ALNY, SEC CIK 1178670) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Alnylam Pharmaceuticals (ALNY) reported revenue of $3.7 billion (up 65.2% from FY2024) and net income of $313.7 million. Diluted EPS was $2.33.
- As of September 30, 2026, 38 institutional investment managers tracked by SignalX reported holding Alnylam Pharmaceuticals (ALNY) shares worth $10.9 billion in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Sigal Charles Elliott on November 10, 2026 of 1,600 shares at $152.25 per share.
- In the last 90 days, ALNY insiders reported 2 open-market purchases ($543K) and 1 open-market sale ($399K) on Form 4, a net purchase of $144K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $3.7B
- +65.2% vs prior year
- Insiders · 90 days
- 2 buys · 1 sell
- Net +$144K
- 13F holders
- 38 funds
- $10.9B · −1 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 5.02 · Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Achieved first profitability in 2025 with net product revenues approx. $3.0B, primarily from TTR franchise growth
- Initiated Phase 3 trials in 2025 for nucresiran (next-gen TTR silencer) and zilebesiran (hypertension), emphasizing late-stage pipeline expansion
- Strategic focus on Alnylam 2030: 10 tissue types, 40+ clinical programs, 30% revenues in R&D, 25%+ CAGR, targeting two blockbusters beyond TTR
- Net product revenues up 81% YoY to $2.99B driven by AMVUTTRA growth (+138% to $2.31B), offset by ONPATTRO decline (-32% to $173M)
- Paid $1.15B to repurchase convertible notes in 2025; raised $645.7M from 0.00% Convertible Senior Notes due 2028 issuance
Risk Factors
- Regulatory risk from U.S. drug price control measures, Medicare/Medicaid reimbursement changes potentially reducing AMVUTTRA net price
- Geopolitical exposure to foreign currency fluctuations in Japanese yen, Euro, and British pound affecting revenues and expenses
- Operational reliance on third-party manufacturing and clinical trial partners to supply and develop AMVUTTRA and other products
- Market disruption risk from generic competition and emerging therapies targeting ATTR-CM and hATTR-PN indications
- Financial risk tied to royalty sale of Leqvio with $1.00B sales threshold by 12/31/2029 impacting future royalty retention percentages
AI summary of the ALNY 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New regulatory risk: October 2025 subpoena on government price reporting for four products, with U.S. Attorney engagement continuing
- New legal risk: Cipla’s September 2026 lawsuit challenging AMVUTTRA patents through an FDA generic application
- Operational risk: AMVUTTRA generic competition could affect product sales following Cipla’s abbreviated new drug application
- Financial risk: $362.8 million of 2027 convertible notes classified current, maturing September 15, 2027
- Collaboration risk: Regeneron’s Initial Research Term expired in May 2026, ending exclusivity for new eye and CNS discovery programs
Management Discussion & Analysis
- Q3 revenue $1.458B, up from $1.249B YoY, a $209.1M increase
- Operating margin 23.7% vs 29.5% YoY, net income $2.167B vs $292.7M
- Best performer AMVUTTRA: $1.130B revenue vs $685.3M, up $445.1M
- Worst performer ONPATTRO: $19.6M revenue vs $39.1M, down $19.5M
- Nine-month operating cash flow $738.2M vs $306.4M, with $700.7M used in investing activities
AI summary of the ALNY 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Chief Commercialization Officer Tolga Tanguler departing in December 2026
- Planned written separation agreement, terms not yet disclosed
Item 8.01: Other Events
- $1.0 billion share repurchase authorization, signaling capital return and potential support for ALNY’s stock
- Approximately $500 million targeted for repurchase by end-2026, with the balance planned during 2027
Item EX-99.1: Item EX-99.1
- Q3 revenue $1.46B, up 17%, led by net product revenue $1.29B, up 52%, reinforcing commercial momentum
- AMVUTTRA revenue $1.13B, up 65%, while ONPATTRO fell 50% to $20M, signaling portfolio migration toward newer therapy
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full earnings release in Exhibit 99.1, the key source for revenue, profitability and guidance details
Item 2.02: Results of Operations and Financial Condition
- Alnylam announced financial results for the quarter ended June 30, 2026
- Detailed operating results and management commentary contained in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $1.291B, up 67%, with GAAP net income $164.5M versus a $72.2M loss
- AMVUTTRA revenue $1.012B, up 106%, driving total TTR revenue $1.030B, up 89%
AI summaries of ALNY 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ALNY
Don't miss the next ALNY filing
- Alerts as it files. A push when ALNY files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ALNY, by share count.
- Ask anything. An AI agent that reads every ALNY filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Greenstreet Yvonne | G | Nov 13, 2026 | 11,000 | - |
| PYOTT DAVID E I | M | Nov 10, 2026 | 3,780 | $71.99 |
| PYOTT DAVID E I | M | Nov 10, 2026 | 3,780 | - |
| Sigal Charles Elliott | Buy | Nov 10, 2026 | 1,600 | $152.25 |
| SCHULMAN AMY W | Buy | Nov 9, 2026 | 1,910 | $156.82 |
| SUPRAN BRYAN | Sell | Oct 2, 2026 | 1,758 | $226.88 |
| Greenstreet Yvonne | A | Sep 19, 2026 | 107 | - |
| SCHULMAN AMY W | M | May 13, 2026 | 11,250 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $2.2B | $3.7B |
| Operating Income | - | -$176.9M | $501.6M |
| Net Income | -$440.2M | -$278.2M | $313.7M |
| Op. Margin | - | -7.9% | 13.5% |
| Net Margin | - | -12.4% | 8.4% |
| Balance Sheet | |||
| Total Assets | $3.8B | $4.2B | $5.0B |
| Equity | - | $67.1M | $789.2M |
| ROE | - | -414.6% | 39.8% |
| Per Share | |||
| EPS | $-3.52 | $-2.18 | $2.33 |
| Cash Flow | |||
| Operating CF | - | -$8.3M | $524.1M |
| CapEx | $62.2M | $34.3M | $58.7M |
Source: XBRL data in Alnylam Pharmaceuticals (ALNY)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ALNY share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 38 | $10.93B |
| Q2 2026 | 39 | $18.03B |
| Q1 2026 | 38 | $20.78B |
| Q4 2025 | 36 | $24.88B |
| Q3 2025 | 39 | $30.03B |
| Q2 2025 | 34 | $19.81B |
| Q1 2025 | 33 | $12.52B |
| Q4 2024 | 29 | $9.27B |
- AQR Capital Management+971.8K (+133%)
- Bank of America Corp+737.9K (+74%)
- State Street Corp+261.6K (+7%)
- Goldman Sachs Group+204.0K (+35%)
- Vanguard Portfolio Management LLC+159.5K (+2%)
- Two Sigma Investments−1.03M (-55%)
- JPMorgan Chase & Co−953.3K (-36%)
- T. Rowe Price Group−397.6K (-35%)
- Raymond James Financial−296.7K (-76%)
- Ameriprise Financial−145.4K (-71%)
- FMR LLC (Fidelity)−15.02M
- Citadel Advisors LLC−191.0K
- Allstate−8.2K
- Marex Group plc−711
Source: 13F-HR filings on SEC EDGAR (aggregated from 286 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ALNY filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 10-Q | Oct 29, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 6, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 10-Q | Jul 30, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | May 27, 2026 | - | Analysis | |
| 4 | May 14, 2026 | - | - | |
| 8-K | Apr 30, 2026 | - | Analysis | - |
| 10-Q | Apr 30, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | Apr 29, 2026 | - | - | |
| 4 | Apr 7, 2026 | - | - | - |
| 4 | Mar 6, 2026 | - | - | - |
| 4 | Mar 6, 2026 | - | - | - |
| 4 | Mar 6, 2026 | - | - | - |
| 4 | Mar 6, 2026 | - | - | - |
| 4 | Mar 6, 2026 | - | - | - |
| 8-K | Mar 4, 2026 | - | Analysis | - |
| 4 | Mar 4, 2026 | - | - | - |
| 4 | Mar 4, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ALNY SEC filings: frequently asked questions
Are ALNY insiders buying or selling?
In the last 90 days, Alnylam Pharmaceuticals (ALNY) officers, directors and 10% owners reported 2 open-market purchases worth $543,126 by 2 insiders and 1 open-market sale worth $398,855 by 1 insider on Form 4, a net purchase of $144,271. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ALNY stock?
As of September 30, 2026, the largest Alnylam Pharmaceuticals (ALNY) holders among the 13F filers tracked by SignalX were BlackRock ($2.7 billion), Vanguard Portfolio Management LLC ($1.7 billion), Vanguard Capital Management LLC ($1.5 billion), State Street Corp ($941.9 million), Invesco Ltd ($922.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ALNY's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Alnylam Pharmaceuticals (ALNY) reported revenue of $3.7 billion (up 65.2% from FY2024) and net income of $313.7 million. Diluted EPS was $2.33. The figures come from the XBRL data in the 10-K.
What are the main risks in ALNY's latest 10-K?
In the 10-K filed February 12, 2026, Alnylam Pharmaceuticals (ALNY) flagged: Regulatory risk from U.S. drug price control measures, Medicare/Medicaid reimbursement changes potentially reducing AMVUTTRA net price. Geopolitical exposure to foreign currency fluctuations in Japanese yen, Euro, and British pound affecting revenues and expenses. (AI summary of the Risk Factors section.)
What did ALNY report in its latest 8-K?
Alnylam Pharmaceuticals (ALNY) filed an 8-K on November 5, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers) and Item 8.01 (Other Events). Chief Commercialization Officer Tolga Tanguler departing in December 2026.
What are the latest ALNY SEC filings?
Alnylam Pharmaceuticals (ALNY) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 17, 2026.
What is ALNY's SEC CIK number?
Alnylam Pharmaceuticals (ALNY)'s SEC Central Index Key (CIK) is 1178670. EDGAR lists every ALNY filing under that number.
Ask anything about ALNY
The research agent reads ALNY's filings, financials, insider trades and 13F holders, then answers with sources.